Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Snatches ImClone Away From Bristol

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.

Related Content

Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang On Lilly's FIPNET Strategies In China
Isis Reacquires Cancer Compound From Lilly To Develop In-House
Amylin Chair And Lead Independent Director Voted Off The Board
Why Carl Icahn May Not Get His Way At Biogen Idec
Shareholder Activism As Public Venture Capital? In Some Cases, It’s Icahn’s Approach
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer
Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Amylin Speculation Intensifies, Part 2: Activist Shareholders Grow Restless
Bristol Sweetens ImClone Bid A Bit, Plans To Ask Stockholders To Replace Board





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts